Superluminal Medicines
✓ Verified
Healthcare AI
AI drug discovery / small-molecule therapeutics / GPCRs
Series B
Superluminal Medicines is a Boston-based biotechnology company that uses generative biology, machine learning, AI-powered computational methods, structural biology, and experimental validation to discover and develop small-molecule therapeutics, with an initial focus on GPCR targets and cardiometabolic diseases, including obesity. The company’s platform, called Hyperloop, is designed to accelerate candidate-ready compound generation and validation.
Company Details
- Website
- superluminalrx.com
- Headquarters
- Boston, Massachusetts, US
- Founded
- 2023
- Funding
- $213M
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring